Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

32.40
+1.926.30%
Post-market: 32.400.00000.00%18:18 EST
Volume:1.01M
Turnover:32.89M
Market Cap:1.85B
PE:47.32
High:33.48
Open:31.70
Low:31.06
Close:30.48
52wk High:38.69
52wk Low:5.35
Shares:57.12M
Float Shares:38.09M
Volume Ratio:1.70
T/O Rate:2.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6847
EPS(LYR):-1.6475
ROE:15.02%
ROA:5.20%
PB:6.01
PE(LYR):-19.67

Loading ...

Stoke Therapeutics präsentiert auf dem Guggenheim Emerging Outlook: Biotech Summit

Reuters
·
Feb 05

Will Stoke’s New Waltham Headquarters for Zorevunersen Commercialization Shift Stoke Therapeutics' (STOK) Narrative?

Simply Wall St.
·
Feb 02

Stoke Therapeutics Signs Lease for New 98,500-Square-Foot Headquarters in Waltham

Reuters
·
Jan 28

How Accelerated EMPEROR Enrollment and Expedited FDA Talks At Stoke Therapeutics (STOK) Have Changed Its Investment Story

Simply Wall St.
·
Jan 25

Stoke Therapeutics (STOK) Valuation Check As Phase 3 Dravet Study Advances And FDA Discussions Progress

Simply Wall St.
·
Jan 22

Stoke Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Jan 17

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 17

Stoke Therapeutics Down Over 16%, on Pace for Largest Percent Decrease Since February 2024 -- Data Talk

Dow Jones
·
Jan 13

Stoke Therapeutics to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 13

Stoke Therapeutics updates timeline for Phase 3 EMPEROR study

TIPRANKS
·
Jan 12

Stoke Therapeutics Showcases Pipeline Advancements for Dravet Syndrome and Rare Genetic Diseases

Reuters
·
Jan 12

BRIEF-Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen

Reuters
·
Jan 12

Stoke Therapeutics Accelerates Phase 3 EMPEROR Study Enrollment for Dravet Syndrome Drug Zorevunersen

Reuters
·
Jan 12

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout From the Emperor Study of Zorevunersen for the Treatment of Dravet Syndrome

THOMSON REUTERS
·
Jan 12

Stoke Therapeutics Inc: Expects to Complete Enrollment of 150 Patients in Q2 2026, With a Phase 3 Data Readout in Mid-2027

THOMSON REUTERS
·
Jan 12

Stoke Therapeutics Inc - Continues to Explore Potential for Expedited Development, Registration and Delivery of Zorevunersen to Patients

THOMSON REUTERS
·
Jan 12

Stoke Therapeutics Inc : Canaccord Genuity Raises Target Price to $36 From $28

THOMSON REUTERS
·
Jan 05

Stoke Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Dec 17, 2025

Stoke Therapeutics Inc : H.c. Wainwright Raises Target Price to $50 From $35

THOMSON REUTERS
·
Dec 15, 2025

Stoke Therapeutics Director Edward M. Kaye MD Reports Sale of Common Shares

Reuters
·
Dec 11, 2025